Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection
El-Khoury et al., Cancers, 2020
Lung cancer is the deadliest cancer worldwide, mainly due to its advanced stage at the time of diagnosis. A non-invasive method for its early detection remains mandatory to improve patients’ survival.
The proteomics platform participated to the validation of a biomarker panel in 48 patients and 49 healthy volunteers. A 6-protein panel clearly distinguished lung cancer from healthy individuals. The panel displayed excellent performance: area under the receiver operating characteristic curve (AUC) = 0.999, positive predictive value (PPV) = 0.992, negative predictive value (NPV) = 0.989, specificity = 0.989 and sensitivity = 0.992. The panel detected lung cancer independently of the disease stage.
This article illustrates targeted mass spectrometry as an emerging antibody-free platform for the validation of protein-based diagnostic assays.
Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg
Competence Center for Methodology and Statistics, Luxembourg Institute of Health, Strassen, Luxembourg
Quantitative Biology Unit, Luxembourg Institute of Health, Strassen Luxembourg
Collaborative Center for Translational Mass Spectrometry, Phoenix, USA
Fred Hutchinson Cancer Research Center, Seattle, USA
Department of Cancer Biology, Mayo Clinic, Scottsdale, USA
Norton Thoracic Institute, Phoenix, USA
Department of cardiac surgery, Luxembourg, Luxembourg
Zithaklinik, Luxembourg , Luxembourg
Department of Biomedicine, University of Bergen, Norway
Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg